Genetron will provide clinical trial genomic testing and companion diagnostic development services for InnoCare's biomarker-driven oncology drug development.
The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.
Among the firms presenting, drugmakers, speciality biotechs, and genetic testing firms provided an update on their precision oncology development programs.
